[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 7 of about 7
1. Elô J, Balatoni Z, Kótai Z, Bártfai R: Considerations in the treatment of the node-negative (N0) neck in glottic carcinomas. Pathol Oncol Res; 2002;8(4):257-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prevention is one of the oldest axioms in medicine.
  • On the other hand, overtreatment can cause unnecessary harm to patients.
  • The aim of this assessment is to deal with the diagnosis, predictive factors and surgical therapy of occult metastases of squamous cell cancers originating from the glottic region.
  • Intraoperative cases of open surgery after U-shaped skin preparation up to the hyoid bone with direct inspection of jugular lymph node chain (JLNCh) where the neck was staged.
  • The types of neck dissection were based on the size, shape, number and histological diagnosis of regional nodes.
  • [MeSH-minor] False Negative Reactions. Follow-Up Studies. Glottis. Humans. Laryngectomy / methods. Lymph Node Excision. Lymph Nodes / pathology. Neoplasm Staging. Retrospective Studies. Survival Rate. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngol Rhinol Otol (Stuttg). 1983 Jun;62(6):244-5 [6888114.001]
  • [Cites] Laryngoscope. 1999 May;109(5):795-9 [10334233.001]
  • [Cites] HNO. 1995 Sep;43(9):525-31 [7591863.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1993;250(8):424-8 [8129918.001]
  • [Cites] Acta Otolaryngol. 1992;112(2):383-6 [1605012.001]
  • [Cites] Oncology (Williston Park). 1996 Aug;10(8):1221-6; discussion 1226, 1229 [8869961.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2000 Mar;126(3):360-5 [10722009.001]
  • [Cites] Diagn Ther Endosc. 1994;1(2):69-74 [18493344.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1999 Apr;125(4):388-96 [10208676.001]
  • [Cites] Otolaryngol Clin North Am. 1998 Aug;31(4):639-55 [9687326.001]
  • [Cites] Laryngoscope. 1999 Feb;109(2 Pt 1):212-5 [10890768.001]
  • [Cites] Laryngoscope. 1990 Jan;100(1):54-9 [2293701.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1993;250(8):423 [8129917.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1993;250(8):432-8 [8129920.001]
  • [Cites] Adv Otorhinolaryngol. 1984;32:1-123 [6369947.001]
  • [Cites] Radiology. 1990 Nov;177(2):379-84 [2217772.001]
  • [Cites] Arch Otorhinolaryngol. 1979;225(3):165-80 [548006.001]
  • [Cites] Laryngorhinootologie. 1999 Oct;78(10 ):566-72 [10595342.001]
  • [Cites] HNO. 1996 Feb;44(2):55-60 [8852800.001]
  • [Cites] Oncology (Williston Park). 1995 Jun;9(6):547-54; discussion 554, 557-8 [8719100.001]
  • [Cites] Laryngol Rhinol Otol (Stuttg). 1981 Feb;60(2):63-70 [7218989.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1993;250(8):450-6 [8129924.001]
  • [Cites] Laryngorhinootologie. 1999 Dec;78(12 ):663-70 [10666692.001]
  • (PMID = 12579212.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


2. Body JJ, Mancini I: Bisphosphonates for cancer patients: why, how, and when? Support Care Cancer; 2002 Jul;10(5):399-407
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bisphosphonates (BPs) are potent inhibitors of osteoclast-mediated bone resorption, and it is well accepted that tumor cells in bone, especially breast cancer and myeloma cells, can stimulate osteoclast formation and activity leading to the release of growth factors or cytokines, which will further stimulate cancer cells' growth and their secretion of osteolytic factors.
  • Repeated pamidronate infusions exert clinically relevant analgesic effects in more than half of patients with metastatic bone pain.
  • Lifelong administration of oral clodronate to patients with breast cancer metastatic to bone reduces the frequency of morbid skeletal events by more than one-fourth.
  • Two double-blind randomized placebo-controlled trials comparing monthly 90 mg pamidronate infusions to placebo infusions for 1-2 years in addition to hormone or chemotherapy in patients with at least one lytic bone metastasis have shown that the mean skeletal morbidity rate could be reduced by 30-40%.
  • However, preference can be given to the oral route when BPs are started early in the process of metastatic bone disease in a patient receiving hormone therapy.
  • According to the recently published ASCO guidelines, pamidronate 90 mg i.v. delivered over 2 h every 3-4 weeks can be recommended in patients with metastatic breast cancer who have imaging evidence of lytic destruction of bone and who are concurrently receiving systemic therapy with hormonal therapy or chemotherapy.
  • BPs in women with localized pain whose bone scans were abnormal and plain radiographs normal, but not when an abnormal bone scan is asymptomatic.
  • Because BPs are providing supportive care, reducing the rate of skeletal morbidity but evidently not abolishing it, the criteria for stopping their administration have to be different from those used for classic antineoplastic drugs, and they should not be stopped when metastatic bone disease is progressing.
  • New biochemical markers of bone resorption might help identify those patients continuing to benefit from therapy.
  • Even better results have been achieved in patients with multiple myeloma, and the general consensus is that BPs should be started as soon as the diagnosis of lytic disease is made in myeloma patients.
  • On the other hand, data are scanty in prostate cancer, but large-scale trials with potent BPs are ongoing or planned in such patients.
  • Similar results to those achieved with pamidronate have been obtained with monthly 6-mg infusions of the newer BP ibandronate in patients with breast cancer metastatic to bone.
  • The tolerance of ibandronate could be better, and the drug has the potential to be administered as a 15- to 30-min infusion.
  • For that matter, initial data with clodronate indicate that they have the potential to prevent the development of bone metastases, but the use of BPs in the adjuvant setting must still be viewed as experimental.
  • [MeSH-major] Bone Neoplasms / drug therapy. Diphosphonates / therapeutic use
  • [MeSH-minor] Breast Neoplasms / pathology. Female. Humans. Hypercalcemia / etiology. Hypercalcemia / prevention & control. Male. Multiple Myeloma / pathology. Neoplasm Metastasis / prevention & control. Prostatic Neoplasms / pathology. Randomized Controlled Trials as Topic

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12136223.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Diphosphonates
  • [Number-of-references] 59
  •  go-up   go-down


3. Abd El-Aal H: Role of radio-iodinated meta-iodo benzyl guanidine in assessment of children with neuroblastoma at NEMROCK. J Egypt Natl Canc Inst; 2006 Dec;18(4):375-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MIBG has been successfully used in diagnosis and staging of children with neuroblastoma.
  • PATIENTS AND METHODS: Twenty eight patients with neuroblastoma attending the Pediatric Oncology Unit, Kasr El-Aini Center of Radiation Oncology and Nuclear Medicine (NEMROCK), Cairo University, over a period of 5 years (2002-2006) were assessed by MIBG scanning.
  • They were 16 boys and 12 girls with a M:F ratio of 1:3, none was stage I and II, 7 patients (25%) were stage III and 21 patients (75%) were stage IV (Evan's staging system).
  • Metastases were present in the bone marrow in 11 children (39.3%), lymph nodes in 5 (17.9%), CNS in 4 (14.3%), liver in 2 (7.1%), soft tissues in 3 (10.7%), lungs and pleura in 1 (3.6%), brain in 1 (3.6%), and testis in 1 patient (3.8%).
  • On the other hand, low VMA levels were associated with cardiac uptake of (131)I MIBG in 3/4 patients with a specificity of 75%, a PPV of 88% and NPV of 86.7%. (131)I MIBG scintigraphy and bone marrow aspiration agreed on detecting neuroblastoma lesions in 24 /28 patients (85.7%) p<0.01, with a sensitivity of 59.5%, specificity of 96.6%.
  • CONCLUSION: (131)I MIBG scintigraphy, in a dose of 2 mci can be used with 87.5% accuracy in the diagnosis and follow-up of Children with neuroblastoma.
  • [MeSH-major] 3-Iodobenzylguanidine. Abdominal Neoplasms / diagnosis. Iodine Radioisotopes. Mediastinal Neoplasms / diagnosis. Neuroblastoma / diagnosis
  • [MeSH-minor] Biopsy, Needle. Bone Marrow / pathology. Bone and Bones / drug effects. Bone and Bones / metabolism. Child. Child, Preschool. Egypt. Female. Heart / drug effects. Humans. Infant. Male. Myocardium / metabolism. Neoplasm Staging. Retrospective Studies. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18301461.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 35MRW7B4AD / 3-Iodobenzylguanidine
  •  go-up   go-down


Advertisement
4. Ito Y, Osaki Y, Tokudome N, Sugihara T, Takahashi S, Iwase T, Hatake K: Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer: cross-resistance to capecitabine. Breast Cancer; 2009;16(2):126-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No grade 3 was seen as hand-foot syndrome.
  • Neither grade 3 nor 4 was observed in bone marrow suppression.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Bone Neoplasms / drug therapy. Breast Neoplasms / drug therapy. Drug Resistance, Neoplasm. Liver Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Pleural Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anthracyclines / administration & dosage. Bridged Compounds / administration & dosage. Capecitabine. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drug Combinations. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Humans. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Taxoids / administration & dosage. Treatment Outcome


5. Ambros PF, Méhes G, Ambros IM, Luegmayr A, Ladenstein R, Gadner H: [Detection, quantification and characterization of disseminated tumor cells]. Acta Med Austriaca Suppl; 2002;59:58-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On the one hand the detection of disseminated tumor cells can provide vital information about a tumor's tendency to develop metastases.
  • Another important aspect is the monitoring of the disease response to cytotoxic drugs by quantifying DTCs.
  • During and after therapy there is no other possibility (except for an operation) to either directly analyze the effects the therapy has on the tumor cells or to determine their biological characteristics.
  • The dissemination in the hematopoetic system, however, reveals the response to therapy and the biological features of the tumor cells.
  • The prerequisites for such bone-marrow diagnosis, however, is the unequivocal identification of disseminated tumor cells.
  • So in order to avoid false positive results (which are a risk in bone-marrow diagnostics), a system was developed to distinguish tumor cells from non-neoplastic cells and to facilitate insights into the biological make-up of tumor cells (2, 11).
  • [MeSH-major] Bone Marrow / pathology. Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Hematopoiesis. Humans. Monitoring, Physiologic / methods. Neoplasm Staging. Reproducibility of Results

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12506762.001).
  • [ISSN] 0303-8181
  • [Journal-full-title] Acta medica Austriaca. Supplement
  • [ISO-abbreviation] Acta Med Austriaca Suppl
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


6. Mickisch GH: Early versus deferred hormonal treatment for asymptomatic prostate cancer. Onkologie; 2001 Jun;24(3):214-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There are two different clinical scenarios in which a decision on hormonal therapy either initially after diagnosis of deferred until the occurrence of signs and symptoms for presently asymptomatic prostate cancer is needed: A more recently described cohort of men with prostate cancer who underwent definitive therapy for putatively curable disease experiencing a rising PSA (biochemical relapse / progression), and a more classical group of men with prostate cancer who were unwilling or unfit to undergo local therapy with curative intent.
  • On the other hand, a potential prolongation of survival and a delay in the development of clinical symptoms may serve as arguments for early treatment.
  • A number of studies have been conducted in which early hormonal treatment delays the time to progression and reduces the cancer-related complication rate such as urinary obstruction and bone fractures.
  • [MeSH-major] Antineoplastic Agents, Hormonal / administration & dosage. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Clinical Trials as Topic. Drug Administration Schedule. Humans. Male. Middle Aged. Neoplasm Staging. Quality of Life. Survival Analysis

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger GmbH, Freiburg
  • (PMID = 11455213.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng; ger
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal
  • [Number-of-references] 28
  •  go-up   go-down


7. Pflüger T, Schmid I, Coppenrath E, Weiss M: Modern nuclear medicine evaluation of neuroblastoma. Q J Nucl Med Mol Imaging; 2010 Aug;54(4):389-400
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modern nuclear medicine evaluation of neuroblastoma.
  • Therefore, exact staging with radiological and nuclear medicine imaging methods is crucial for finding the adequate therapeutic choice.
  • The tumor cells express the norepinephrine transporter, which makes metaiodobenzylguanidine (MIBG), an analogue of norepinephrine, an ideal tumor specific agent for imaging.
  • On the other hand, MIBG imaging has several disadvantages as limited spatial resolution, limited sensitivity in small lesions, need for two or even more acquisition sessions, and a delay between the start of the examination and result.
  • This article will discuss the therapeutic strategy for primary and follow-up diagnosis in neuroblastoma using different nuclear medicine and radiological imaging methods as well as multimodality imaging.
  • [MeSH-minor] 3-Iodobenzylguanidine. Bone Neoplasms / diagnosis. Bone Neoplasms / radionuclide imaging. Child. Humans. Magnetic Resonance Imaging. Neoplasm Staging / methods. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20823807.001).
  • [ISSN] 1824-4785
  • [Journal-full-title] The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology
  • [ISO-abbreviation] Q J Nucl Med Mol Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 35MRW7B4AD / 3-Iodobenzylguanidine
  •  go-up   go-down






Advertisement